NRF1 and steatosis: Moreover, Nrf1 and Nrf2 were each required for 2-week treatment with the Nrf2-activating drug bardoxolone to reduce steatosis and inflammation in mice chronically fed the MASH-inducing HFFC diet for 24 weeks, and combining this with hepatocyte overexpression of human NRF1 potentiated such effects in mice fed an HFFC diet for 16 weeks.